Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics

[1]  C. Larsson,et al.  Detailed assessment of copy number alterations revealing homozygous deletions in 1p and 13q in mantle cell lymphoma. , 2007, Leukemia research.

[2]  E. Reddy,et al.  Evaluation of novel cell cycle inhibitors in mantle cell lymphoma , 2007, Oncogene.

[3]  A. Rosenwald,et al.  Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis. , 2007, Blood.

[4]  Adrian Wiestner,et al.  Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. , 2007, Blood.

[5]  E. Campo,et al.  The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. , 2007, Blood.

[6]  G. Schwarzer,et al.  Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. , 2007, Journal of the National Cancer Institute.

[7]  A. Tolcher,et al.  Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  L. Staudt,et al.  Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  B. Johansson,et al.  The impact of translocations and gene fusions on cancer causation , 2007, Nature Reviews Cancer.

[10]  A. Rosenwald,et al.  Increased MDM2 expression is associated with inferior survival in mantle-cell lymphoma, but not related to the MDM2 SNP309. , 2007, Haematologica.

[11]  Michele Pallaoro,et al.  HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics , 2007, Cell Research.

[12]  S. Cory,et al.  The Bcl-2 apoptotic switch in cancer development and therapy , 2007, Oncogene.

[13]  E. Campo,et al.  Selective Inhibition of IκB Kinase Sensitizes Mantle Cell Lymphoma B Cells to TRAIL by Decreasing Cellular FLIP Level1 , 2007, The Journal of Immunology.

[14]  E. Campo,et al.  Unbalanced expression of licensing DNA replication factors occurs in a subset of mantle cell lymphomas with genomic instability , 2006, International journal of cancer.

[15]  J. Leonard,et al.  Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  B. Sola,et al.  Relevance of cyclin D1b expression and CCND1 polymorphism in the pathogenesis of multiple myeloma and mantle cell lymphoma , 2006, BMC Cancer.

[17]  G. Georgakis,et al.  The heat shock protein 90 inhibitor 17‐AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9 , 2006, British journal of haematology.

[18]  E. Jaffe,et al.  Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. , 2006, Blood.

[19]  P. Nowell,et al.  Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. , 2006, Blood.

[20]  H. Drexler,et al.  Mantle cell lymphoma-derived cell lines: unique research tools. , 2006, Leukemia research.

[21]  E. Campo,et al.  Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines. , 2006, Leukemia research.

[22]  J C Reed,et al.  Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins , 2006, Cell Death and Differentiation.

[23]  D. Weisenburger,et al.  A chromosomal translocation in cyclin D1-negative/cyclin D2-positive mantle cell lymphoma fuses the CCND2 gene to the IGK locus. , 2006, Blood.

[24]  R. Advani,et al.  Treatment of mantle cell lymphoma: current approach and future directions. , 2006, Critical reviews in oncology/hematology.

[25]  R. Siebert,et al.  Partial uniparental disomy: a recurrent genetic mechanism alternative to chromosomal deletion in malignant lymphoma , 2006, Leukemia.

[26]  M. Wasik,et al.  Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma , 2006, Oncogene.

[27]  Francesco Bertoni,et al.  Genomic and expression profiling identifies the B‐cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma , 2006, British journal of haematology.

[28]  W. Hiddemann,et al.  Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors [p16(INK4a), p15(INK4b), p14(ARF)] in mantle cell lymphoma , 2006, Genes, chromosomes & cancer.

[29]  Chen-feng Qi,et al.  Expression of the cyclin-dependent kinase inhibitor p27 and its deregulation in mouse B cell lymphomas. , 2006, Leukemia research.

[30]  G. Cohen,et al.  TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. , 2005, Cancer research.

[31]  L. Staudt,et al.  Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. , 2005, Blood.

[32]  B. Sander,et al.  Mantle cell lymphomas with low levels of cyclin D1 long mRNA transcripts are highly proliferative and can be discriminated by elevated cyclin A2 and cyclin B1 , 2005, International journal of cancer.

[33]  S. Serrano,et al.  Clonal proliferation of cyclin D1-positive mantle lymphocytes in an asymptomatic patient: an early-stage event in the development or an indolent form of a mantle cell lymphoma? , 2005, Human pathology.

[34]  T. A. Lister,et al.  Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. , 2005, Cancer research.

[35]  W. Klapper,et al.  Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network , 2005, British journal of haematology.

[36]  A. Rosenwald,et al.  Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  T. Witzig.  Current treatment approaches for mantle-cell lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  O. O’Connor.  Targeting histones and proteasomes: new strategies for the treatment of lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  B. Aggarwal,et al.  Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. , 2005, Biochemical pharmacology.

[40]  John Calvin Reed,et al.  Apoptosis-based therapies for hematologic malignancies. , 2005, Blood.

[41]  F. Cavalli,et al.  In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  D. Pinkel,et al.  Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. , 2005, Blood.

[43]  Ralf Küppers,et al.  Mechanisms of B-cell lymphoma pathogenesis , 2005, Nature Reviews Cancer.

[44]  A. Rosenwald,et al.  CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus. , 2005, Cancer research.

[45]  C. Larsson,et al.  Mantle cell lymphomas with clonal immunoglobulin VH3–21 gene rearrangements exhibit fewer genomic imbalances than mantle cell lymphomas utilizing other immunoglobulin VH genes , 2005, Modern Pathology.

[46]  S. Cajal,et al.  Immunohistochemical analysis of ZAP‐70 expression in B‐cell lymphoid neoplasms , 2005, The Journal of pathology.

[47]  H. Tagawa,et al.  Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM , 2005, Oncogene.

[48]  Rolph Pfundt,et al.  Novel chromosomal imbalances in mantle cell lymphoma detected by genome-wide array-based comparative genomic hybridization. , 2005, Blood.

[49]  A. Zelenetz,et al.  Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  Michael L. Wang,et al.  Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  R. Maestro,et al.  Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma. , 2005, Cancer research.

[52]  Chenguang Wang,et al.  Minireview: Cyclin D1: normal and abnormal functions. , 2004, Endocrinology.

[53]  S. Zupo,et al.  The CD5+ B-cell. , 2004, The international journal of biochemistry & cell biology.

[54]  A. Bankier,et al.  Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. , 2004, Blood.

[55]  T. McDonnell,et al.  MCL-1 expression in B-cell non-Hodgkin's lymphomas. , 2004, Human pathology.

[56]  D. Steinemann,et al.  Molecular cytogenetic characterization of the mantle cell lymphoma cell line GRANTA-519. , 2004, Cancer genetics and cytogenetics.

[57]  A. Ashkenazi,et al.  Targeting death receptors in cancer with Apo2L/TRAIL. , 2004, Current opinion in pharmacology.

[58]  G. Ott,et al.  Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions. , 2004, Blood.

[59]  L. Dölken,et al.  Low prevalence of circulating t(11;14)(q13;q32)-positive cells in the peripheral blood of healthy individuals as detected by real-time quantitative PCR. , 2004, Blood.

[60]  D. Altieri.  Coupling Apoptosis Resistance to the Cellular Sress Response: The IAP-Hsp90 Connection in Cancer , 2004, Cell cycle.

[61]  D. Altieri.  Human diploid fibroblasts are refractory to oncogene-mediated transformation. , 2004 .

[62]  F. Bosch,et al.  Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. , 2004, The American journal of pathology.

[63]  H. Müller-Hermelink,et al.  VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. , 2003, Blood.

[64]  S. Swerdlow,et al.  Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes. , 2003, Human pathology.

[65]  O. Hermine,et al.  Thalidomide therapy induces response in relapsed mantle cell lymphoma , 2003, Leukemia.

[66]  A. Senderowicz,et al.  Cyclin D1 Splice Variants , 2003, Journal of Biological Chemistry.

[67]  T. Stankovic,et al.  Variations in ATM protein expression during normal lymphoid differentiation and among B-cell-derived neoplasias. , 2003, The American journal of pathology.

[68]  E. Jaffe.  Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues , 2003 .

[69]  Tom Misteli,et al.  Spatial proximity of translocation-prone gene loci in human lymphomas , 2003, Nature Genetics.

[70]  L. Pham,et al.  Inhibition of Constitutive NF-κB Activation in Mantle Cell Lymphoma B Cells Leads to Induction of Cell Cycle Arrest and Apoptosis1 , 2003, The Journal of Immunology.

[71]  D. Catovsky,et al.  A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. , 2003, Blood.

[72]  E. Campo,et al.  Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. , 2003, Blood.

[73]  Emili Montserrat,et al.  ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. , 2003, The New England journal of medicine.

[74]  W. Chan,et al.  Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[75]  E. Campo,et al.  variants of mantle cell lymphoma (MCL): implications for pathogenesis Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic , 2013 .

[76]  Y. Shiloh.  ATM and related protein kinases: safeguarding genome integrity , 2003, Nature Reviews Cancer.

[77]  L. Staudt,et al.  The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. , 2003, Cancer cell.

[78]  T. McDonnell,et al.  Expression of Mcl‐1 in mantle cell lymphoma is associated with high‐grade morphology, a high proliferative state, and p53 overexpression , 2003, The Journal of pathology.

[79]  J. Herman,et al.  CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas. , 2002, Blood.

[80]  O. Coqueret.  Linking cyclins to transcriptional control. , 2002, Gene.

[81]  P. Guldberg,et al.  ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma. , 2002 .

[82]  E. Jaffe,et al.  In situ localization of follicular lymphoma: description and analysis by laser capture microdissection. , 2002, Blood.

[83]  S. Ogawa,et al.  Mutations of Chk2 in primary hematopoietic neoplasms. , 2002, Blood.

[84]  D. Hossfeld.  E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues , 2002 .

[85]  P. Lorigan,et al.  Identification of novel regions of amplification and deletion within mantle cell lymphoma DNA by comparative genomic hybridization , 2002, British journal of haematology.

[86]  Thomas S. Lin,et al.  Seventy-Two Hour Continuous Infusion Flavopiridol in Relapsed and Refractory Mantle Cell Lymphoma , 2002, Leukemia & lymphoma.

[87]  M. Dugan,et al.  Blastic mantle cell lymphoma associated with Burkitt‐type translocation and hypodiploidy , 2001, British journal of haematology.

[88]  Riccardo Dalla-Favera,et al.  Mechanisms of chromosomal translocations in B cell lymphomas , 2001, Oncogene.

[89]  B. Nadel,et al.  Templated nucleotide addition and immunoglobulin JH-gene utilization in t(11;14) junctions: implications for the mechanism of translocation and the origin of mantle cell lymphoma. , 2001, Cancer research.

[90]  J L Cleveland,et al.  Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. , 2000, Genes & development.

[91]  S. Elledge,et al.  The DNA damage response: putting checkpoints in perspective , 2000, Nature.

[92]  H. Döhner,et al.  Mantle cell lymphoma is characterized by inactivation of the ATM gene. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[93]  Michael Baudis,et al.  t(11;14)‐positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B‐cell chronic lymphocytic leukemia , 2000, Genes, chromosomes & cancer.

[94]  M Chilosi,et al.  Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. , 2000, Blood.

[95]  M. James,et al.  Molecular characterization of 11q deletions points to a pathogenic role of the ATM gene in mantle cell lymphoma. , 1999, Blood.

[96]  T J Hamblin,et al.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.

[97]  A. López-Guillermo,et al.  Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. , 1999, Blood.

[98]  M. Seto,et al.  Cyclin D1/PRAD1/BCL‐1 alternative transcript [B] protein product in B‐lymphoid malignancies with t(11;14)(q13;q32) translocation , 1999, International journal of cancer.

[99]  R. DePinho,et al.  The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus , 1999, Nature.

[100]  M. Roussel,et al.  Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. , 1998, Genes & development.

[101]  A. López-Guillermo,et al.  Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. , 1998, Cancer.

[102]  W. Hiddemann,et al.  Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma. , 1997, Cancer research.

[103]  E. Schuuring,et al.  Visualization of mono-allelic chromosomal aberrations 3′ and 5′ of the cyclin D1 gene in mantle cell lymphoma using DNA fiber fluorescence in situ hybridization , 1997, Oncogene.

[104]  H. Müller-Hermelink,et al.  Blastoid variants of mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. , 1997, Blood.

[105]  C. Croce,et al.  Characterization of t(11;14) translocation in mantle cell lymphoma by fluorescent in situ hybridization. , 1996, Oncogene.

[106]  E. Schuuring,et al.  Direct visualization of dispersed 11q13 chromosomal translocations in mantle cell lymphoma by multicolor DNA fiber fluorescence in situ hybridization. , 1996, Blood.

[107]  N. Harris,et al.  Expression of the Retinoblastoma Protein in Low-Grade B-Cell Lymphoma: Relationship to Cyclin D1 , 1996 .

[108]  M. Callanan,et al.  Molecular diagnosis of t(11;14) in mantle cell lymphoma using two‐colour interphase fluorescence in situ hybridization , 1996, British journal of haematology.

[109]  W. Chan,et al.  p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. , 1996, Blood.

[110]  F. Bosch,et al.  Expression of retinoblastoma gene product (pRb) in mantle cell lymphomas. Correlation with cyclin D1 (PRAD1/CCND1) mRNA levels and proliferative activity. , 1996, The American journal of pathology.

[111]  F. Bosch,et al.  p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. , 1996, Blood.

[112]  N Thatcher,et al.  Alternate splicing produces a novel cyclin D1 transcript. , 1995, Oncogene.

[113]  E. Schuuring,et al.  Cyclin D1 messenger RNA overexpression as a marker for mantle cell lymphoma. , 1995, Oncogene.

[114]  D. Jong,et al.  Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. , 1995, Blood.

[115]  T. Hunter,et al.  Cyclins and cancer II: Cyclin D and CDK inhibitors come of age , 1994, Cell.

[116]  A. López-Guillermo,et al.  PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma , 1994 .

[117]  M. Seto,et al.  A variant chromosome translocation at 11q13 identifying PRAD1/cyclin D1 as the BCL-1 gene. , 1994, Blood.

[118]  H. Lovec,et al.  Cyclin D1/bcl‐1 cooperates with myc genes in the generation of B‐cell lymphoma in transgenic mice. , 1994, The EMBO journal.

[119]  J.M. Adams,et al.  Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. , 1994, The EMBO journal.

[120]  F. Berger,et al.  Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas. , 1994, Blood.

[121]  R. Weinberg,et al.  Function of a human cyclin gene as an oncogene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[122]  David M. Livingston,et al.  Functional interactions of the retinoblastoma protein with mammalian D-type cyclins , 1993, Cell.

[123]  S. Pileri,et al.  Mantle Cell Lymphoma , 2022, The EBMT/EHA CAR-T Cell Handbook.

[124]  Y. Akao,et al.  Gene rearrangement and overexpression of PRAD1 in lymphoid malignancy with t(11;14)(q13;q32) translocation. , 1992, Oncogene.

[125]  M. Raffeld,et al.  bcl-1, t(11;14), and mantle cell-derived lymphomas. , 1991, Blood.

[126]  T. Lister,et al.  Centrocytic lymphoma: a distinct clinicopathologic and immunologic entity. A multiparameter study of 18 cases at diagnosis and relapse. , 1983, The American journal of pathology.

[127]  E. Jaffe,et al.  Alkaline phosphatase-positive malignant lymphoma. A subtype of B-cell lymphomas. , 1977, American journal of clinical pathology.

[128]  Ronald Breslow,et al.  Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug , 2007, Nature Biotechnology.

[129]  T. Haritunians,et al.  Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma , 2007, Leukemia.

[130]  E. Campo,et al.  Mantle cell lymphoma: from pathology and molecular pathogenesis to new therapeutic perspectives. , 2006, Haematologica.

[131]  E. Campo,et al.  The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. , 2006, Blood.

[132]  A. Zelenetz,et al.  Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[133]  J. Vila-Costas,et al.  [Mantle-cell lymphoma]. , 2006, Gastroenterologia y hepatologia.

[134]  L. Staudt,et al.  Cyclin D 1 – negative mantle cell lymphoma : a clinicopathologic study based on gene expression profiling , 2005 .

[135]  A. Rosenwald,et al.  Checkpoint kinase 1 (CHK1) protein and mRNA expression is downregulated in aggressive variants of human lymphoid neoplasms , 2005, Leukemia.

[136]  H. Koeffler,et al.  Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. , 2005, Experimental hematology.

[137]  C. Peschel,et al.  Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells. , 2005, Haematologica.

[138]  R. Gascoyne,et al.  Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[139]  R. Gascoyne,et al.  Phase II Study of Oral Vinorelbine in First-Line Advanced Breast Cancer Chemotherapy , 2003 .

[140]  J. Herman,et al.  CHK 2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas , 2002 .

[141]  F. Bosch,et al.  ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances. , 2002, Blood.

[142]  R. Gascoyne,et al.  8q24 translocations in blastic transformation of mantle cell lymphoma. , 2000, Haematologica.

[143]  S. Pittaluga,et al.  Secondary chromosome changes in mantle cell lymphoma. , 1999, Haematologica.

[144]  M. James,et al.  Molecular Characterization of 11 q Deletions Points to a Pathogenic Role of the ATM Gene in Mantle Cell Lymphoma , 1999 .

[145]  E. Campo,et al.  Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. , 1997, Blood.

[146]  N. Harris,et al.  Expression of the retinoblastoma protein in low-grade B-cell lymphoma: relationship to cyclin D1. , 1996, Blood.

[147]  A. López-Guillermo,et al.  PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. , 1994, Blood.